Retatrutide (Reta) is an advanced triple agonist that simultaneously targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple-action approach has shown remarkable potential in preclinical studies for significant weight reduction, improved glucose regulation, and enhanced lipid metabolism.

Research Applications & Potential Effects:

• Studies on appetite suppression and body weight reduction

• Research into triple incretin pathway synergy for metabolic health

• Investigations into glucose regulation and insulin sensitivity

• Preclinical evaluation of cardiovascular and lipid profile improvements

Supplied as a sterile, lyophilised powder to ensure maximum purity and stability for precise experimental use.

Molecular Formula: C196H299N53O60
Molar Mass: 4340.85 g/mol
Form: Lyophilised powder
Purity: ≥ 99% (HPLC)
Storage: Store at −20 °C, protect from light
Intended Use: Strictly for research purposes only. Not for human consumption, medical, or veterinary use.
CAS Number: 3044674-34-8